Transplantation of Cardiac Mesenchymal Stem Cell-Derived Exosomes Promotes Repair in Ischemic Myocardium [0.03%]
心脏间充质干细胞衍生物外泌体移植促进心肌缺血修复
Chengwei Ju,Yan Shen,Gengshan Ma et al.
Chengwei Ju et al.
Our previous study demonstrated the beneficial effects of exosomes secreted by cardiac mesenchymal stem cells (C-MSC-Exo) in protecting acute ischemic myocardium from reperfusion injury. Here, we investigated the effect of exosomes from C-M...
New Insights into the Role of Exosomes in the Heart After Myocardial Infarction [0.03%]
心肌梗死后外泌体在心脏中作用的新见解
Na Li,Luc Rochette,Yongxin Wu et al.
Na Li et al.
Intercellular communications play a pivotal role in several cardiac pathophysiological processes. One subtype of extracellular vesicles, so-called exosomes, became known as important intercellular communication mediators in the heart. Exoso...
Yongqin Li,Yajun Liang,Yujiao Zhu et al.
Yongqin Li et al.
Cardiac hypertrophy is classified as pathological and physiological hypertrophy. Pathological hypertrophy typically precedes the onset of heart failure, one of the largest contributors to disease burden and deaths worldwide. In contrast, ph...
Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice [0.03%]
同种异体肌源性前体细胞衍生的外泌体 dystrophin 改善 Duchenne 肌营养不良小鼠的心功能
Xuan Su,Yue Jin,Yan Shen et al.
Xuan Su et al.
Progressive cardiomyocyte loss in Duchenne muscular dystrophy (DMD) leads to cardiac fibrosis, cardiomyopathy, and eventually heart failure. In the present study, we observed that myogenic progenitor cells (MPC) carry mRNA for the dystrophi...
Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases [0.03%]
血清或血浆基质金属蛋白酶(MMP-9)水平与心血管疾病的关系
Indiara V Santana,Jose E Tanus-Santos
Indiara V Santana
Development of a Novel Human Cell-Derived Tissue-Engineered Heart Valve for Transcatheter Aortic Valve Replacement: an In Vitro and In Vivo Feasibility Study [0.03%]
一种用于经导管主动脉瓣置换的新型人源细胞组织工程心脏瓣膜的体内外可行性研究
V Lintas,E S Fioretta,S E Motta et al.
V Lintas et al.
Transcatheter aortic valve replacement (TAVR) is being extended to younger patients. However, TAVR-compatible bioprostheses are based on xenogeneic materials with limited durability. Off-the-shelf tissue-engineered heart valves (TEHVs) with...
Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts [0.03%]
暴发性心肌炎机械辅助降前负荷：LV-IMPELLA、ECMELLA、BI-PPELLA和PROPELLA概念
Carsten Tschöpe,Sophie Van Linthout,Oliver Klein et al.
Carsten Tschöpe et al.
Mechanical circulatory support (MCS) is often required to stabilize patients with acute fulminant myocarditis with cardiogenic shock. This review gives an overview of the successful use of left-sided Impella in the setting of fulminant myoc...
Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction [0.03%]
临床批准的β3肾上腺素受体激动剂ミラベグラfon不减少心肌梗死再灌注猪模型中的梗死范围
Xavier Rossello,Antonio Piñero,Rodrigo Fernández-Jiménez et al.
Xavier Rossello et al.
The administration of the selective β3 adrenergic receptor (β3AR) agonist BRL-37344 protects from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits its translatability. We tested the cardioprotect...
Study of Serum CD147 Level in Patients with Transient Ischemic Attack and CD147 Expression in Atherosclerotic Plaque [0.03%]
短暂性脑缺血发作患者血清CD147水平的变化及动脉粥样硬化斑块中CD147的表达研究
Bin Xu,Chan Wu,Wenqing Wu et al.
Bin Xu et al.
There is growing evidence that highlighted the potential effects of CD147 in atherosclerosis, but the potential implication of CD147 in diagnosis and treatment of transient ischemic attack (TIA) and acute cerebral infarction (ACI) is still ...
Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI) [0.03%]
基于血流储备分数指导的冠脉旁路移植术后移植物通畅性的研究设计（GRAFFITI研究）
Gabor G Toth,Bernard De Bruyne,Petr Kala et al.
Gabor G Toth et al.
Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) ...
Randomized Controlled Trial
Journal of cardiovascular translational research. 2018 Aug;11(4):269-273. DOI:10.1007/s12265-018-9818-9 2018